Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis - Wikidata - awgldk - TriplyDB

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

http://www.wikidata.org/entity/Q33788714

about

Signal transduction in the chronic leukemias: implications for targeted therapies EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.AKT is a therapeutic target in myeloproliferative neoplasms Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow Targeting the interleukin-6/Jak/stat pathway in human malignancies Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Janus kinase 2 inhibitors in myeloproliferative disorders.Mouse models of diseases of megakaryocyte and platelet homeostasis.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Myeloproliferative neoplasm animal models Myelofibrosis 2012: it's complicated.Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.STAT signaling in the pathogenesis and treatment of myeloid malignancies.Preclinical models for drug selection in myeloproliferative neoplasms.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5.Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis.Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.SOHO State-of-the-Art Update and Next Questions: MPN.Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

P2860

Q27026031-E74619A4-1115-4438-BA86-E4C6F5B03227 Q33397674-30528F92-0690-4250-AAA6-505C42C5DED7 Q33417004-7BC5858B-31DF-4514-AD1E-973CE47EAC99 Q33623277-5DE1F670-4E23-487E-991C-562B7479F922 Q33982315-BEBC56C5-26AB-4319-B396-BAC6FB21E8F0 Q34103117-28146B5C-094E-4C01-B42C-999B4DC70DC6 Q34162151-2A1B91C1-3F32-40C0-9CF6-7D139D0FF34E Q34337681-7B6BC543-5F91-4B3E-93FC-EC17DB45D9E5 Q34485103-5B465023-2AC1-45D8-9777-998B876BB8A6 Q34575802-841EAD51-4B97-4E8C-AD96-41685A9C500C Q34752547-EBF29581-DE17-4971-957B-0ADAD3BF9FFE Q35163764-05D6A68E-C52E-496D-B40E-93619AEC1BDE Q35571892-39894A05-B9B0-47A8-A85C-CFD1B54B0B0D Q35925127-F97D63E4-536F-4AA4-8C60-0CEB051B4D77 Q36263805-733143AD-42FF-4BA7-8708-A2B73B88FCC4 Q36359558-4F200980-58DE-4E4E-A556-B7BE7615D846 Q36776428-73618E43-06DB-4ABE-B13C-AF88EBAA62E8 Q37067712-02B6901B-BF50-4D2F-A3F7-645805EAFF44 Q37670068-82091F91-F067-4E7B-AB8F-6BEDE13D9937 Q37697253-FA4A70AB-87A2-46AE-91CE-D4A259D9AEA5 Q37815509-3E73B86F-10F2-4BD7-BE6A-74ADE4EED7E2 Q37888528-254CD33D-4947-4C51-AE60-7817383F49A9 Q38044736-C4F82EB8-F224-4D66-8363-A5B9036F01C6 Q38046320-2B1DF9A9-C9CC-4CCB-B94F-CC142151E887 Q38095967-E55145E0-AD5D-4ABD-97C6-BB981ADEA742 Q38106623-CC79B85D-F91B-4D2A-A9E8-3B9DE9AB4C9F Q38140880-FFD11469-D8BE-4717-97C6-24A5C16EF994 Q38154517-31EEAED9-94B7-4A94-9A6D-37FC5815811D Q38699339-A5C50CBD-F445-4E2F-9F66-33588F9ABB52 Q38747542-1E4C6163-2F1F-4790-981E-4C7E470ACB1A Q38824881-7EE8B8A7-D7B6-4C5B-9247-A9894249AA0B Q38848273-91854572-0445-464F-9382-46A1EAA867BE Q41418744-0EEF13CD-99A2-45B0-BDB1-63AEE1A31905 Q41787058-92CC6920-2903-4E6C-A9F8-64F5B1792E27 Q42106569-30E49A64-324C-4C14-A59F-FF799023DDC6 Q42157999-5E4BE155-A030-4A30-B274-60377F8985CB Q42180113-4FCC43E3-5CDE-4215-8AAA-B1954EA28101 Q48569638-0AF56F63-51D5-4987-ABEF-24E72BD18C03 Q49580473-51005BDA-5AAA-4045-8900-E894B38A8ED5 Q49834761-9EC5C3AF-34E9-4312-8A4B-9C8319CBA344

P2860

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

http://www.wikidata.org/entity/Q33788714

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@ast

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@en

type

label

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@ast

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@en

prefLabel

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@ast

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@en

P1433

Q33788714-65162F2E-D97F-4E00-9E98-C2A70D7ED7B3

P1476

Q33788714-82BE66D7-DCDF-4A50-86D6-EEC4F05DA10F

P2093

Q33788714-0616FF94-7D85-452B-B7DE-9DD6894DC81C

Q33788714-21DCF19B-2A0E-4DBA-B517-6AF44C9E5D25

Q33788714-4E041119-3BB5-4CFD-A6B3-62C39E74EDF8

Q33788714-560A792D-567A-4FCB-8351-76645CA17AEA

Q33788714-635FBD38-9943-4593-B1C3-A90C3D63FEAB

Q33788714-7E64DCA7-B171-42E8-A145-20849D2AF9DB

Q33788714-9648371F-D9DA-4F9E-ADBD-BDD203B3BBDF

Q33788714-9FC6DEEB-013D-45B3-BFCA-793D2117BA37

Q33788714-B74CF93D-4FF0-4D97-BA59-B9C7FF0C29EB

Q33788714-BF9C4672-0237-4DAF-8405-5C9379B4B787

P2860

Q33788714-1A7C38BC-22C7-4B83-A161-8700C97506B3

Q33788714-1BA4AB37-CA79-44C7-8BBB-F622DE4D0FC0

Q33788714-32B8829E-E906-4299-B54F-EDD152AC47BD

Q33788714-42703CE1-58F2-462E-9676-442FE0A2C697

Q33788714-457D4A16-41A9-472A-ABCF-6FAF0E76C6EC

Q33788714-494FC6EE-7F49-43FA-A0D2-5AAA89FC36CD

Q33788714-4E79DCF3-BA9D-4EC2-8DF5-D849710F3142

Q33788714-60FBBDEE-14A9-4CE0-BB6F-C77E33A15F5B

Q33788714-6300BCE0-D1AA-4EC2-9AAB-D66CE0D0A60F

Q33788714-658AB2B2-1A0C-4BD9-9D5B-3C0826C2E710

P304

Q33788714-A715E393-F88F-4043-82BC-768FF05C340A

P31

Q33788714-69484B3C-C5D4-4A4A-BB17-8DCAE8BB44B6

P356

Q33788714-D6B13099-850F-462D-9894-97FB9B3C2DFE

P407

Q33788714-CF4ADA9D-F792-4AC7-8606-C95B46279A15

P433

Q33788714-D95D02A5-AD2A-40A3-A29F-017A7AEFE932

P478

Q33788714-EBF2251B-D083-4488-B8BA-160B09AE4F09

P50

Q33788714-863EB407-6D49-4757-9937-DA6233BF3CE7

Q33788714-CE5C04A4-7825-44D3-B77F-9C288395BC46

P577

Q33788714-833577F7-67FD-45E2-B575-DA0DF29C4BB3

P5875

Q33788714-47030ACA-461F-4878-B8AD-3A53392AF873

P698

Q33788714-4F39A484-FCED-492D-ADCB-B157FB291CFD

P932

Q33788714-B76275E3-F3A1-496F-892C-58CE8F97E463

P356

BLOOD-2009-04-218842

P1433

P1476

Efficacy of the JAK2 inhibitor ...... rombocytosis and myelofibrosis

@en

P2093

Andrew P Combs

http://www.w3.org/2001/XMLSchema#string

Aviva Goel

http://www.w3.org/2001/XMLSchema#string

Elisa de Stanchina

http://www.w3.org/2001/XMLSchema#string

Jacqueline F Bromberg

http://www.w3.org/2001/XMLSchema#string

Jay Patel

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Gardner

http://www.w3.org/2001/XMLSchema#string

Jordan S Fridman

http://www.w3.org/2001/XMLSchema#string

Kris Vaddi

http://www.w3.org/2001/XMLSchema#string

Mark L Heaney

http://www.w3.org/2001/XMLSchema#string

Mark Rupar

http://www.w3.org/2001/XMLSchema#string

P2860

The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A clonogenic common myeloid progenitor that gives rise to all myeloid lineages

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

P304

2919-2927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-04-218842

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Omar Abdel-Wahab

P577

2010-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41428618

http://www.w3.org/2001/XMLSchema#string

P698

20154217

http://www.w3.org/2001/XMLSchema#string

P932

2854434

http://www.w3.org/2001/XMLSchema#string